Sayed Naqvi
Neurology with Special Qualifications in Child Neurology · Miami, FLNPI 1497772404
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 370 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 36 manufacturers reported payments, led by UCB, Inc. at 32.3% of the total.
Across 370 payments — averaging $23.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$3K
- Jazz Pharmaceuticals Inc.$1K
- Neurelis, Inc.$806
- Sunovion Pharmaceuticals Inc.$410
- Greenwich Biosciences, Inc.$405
- SK Life Science, Inc.$269
- plus $3K from 30 others
Across 5 payments — averaging $1341.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Teva Pharmaceuticals USA, Inc.$7K
What the payments were for
- Food & beverage$8,79099%
- Gifts$601%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 91 | $2,854 |
| Jazz Pharmaceuticals Inc. | 43 | $1,203 |
| Neurelis, Inc. | 59 | $806 |
| Sunovion Pharmaceuticals Inc. | 21 | $410 |
| Greenwich Biosciences, Inc. | 20 | $405 |
| SK Life Science, Inc. | 13 | $269 |
| Aquestive Therapeutics, Inc. | 14 | $256 |
| Livanova USA, Inc. | 8 | $245 |
| Sumitomo Pharma America, Inc. | 9 | $220 |
| Medtronic | 2 | $205 |
| Eisai Inc. | 12 | $199 |
| Biogen | 9 | $197 |
| Supernus Pharmaceuticals, Inc. | 10 | $165 |
| Biomarin Pharmaceutical Inc. | 2 | $159 |
| Corium, LLC | 7 | $126 |
| NS Pharma, Inc. | 4 | $98 |
| Zogenix Inc. | 3 | $95 |
| Saol Therapeutics Inc. | 4 | $95 |
| Ironshore Pharmaceuticals Inc. | 5 | $88 |
| Acadia Pharmaceuticals Inc | 2 | $83 |
| Octapharma USA, Inc. | 1 | $83 |
| Catalyst Pharmaceuticals, Inc. | 4 | $67 |
| Neuropace, Inc. | 3 | $67 |
| Azurity Pharmaceuticals, Inc. | 3 | $66 |
| AbbVie(2 entities) | 3 | $61 |
| Immedica Pharma US, Inc. | 2 | $51 |
| Aucta Pharmaceuticals, Inc. | 3 | $50 |
| Aprecia Pharmaceuticals, LLC | 3 | $48 |
| Novartis | 3 | $44 |
| Sarepta Therapeutics, Inc. | 1 | $29 |
| Upsher-smith Laboratories LLC | 1 | $22 |
| Merz Pharmaceuticals, LLC | 1 | $21 |
| Tris Pharma Inc | 1 | $18 |
| Mallinckrodt Enterprises LLC | 1 | $17 |
| Piramal Critical Care | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,850 in reported general payments places this provider in the 70th percentile of 137 neurology with special qualifications in child neurology providers in Florida.
See all neurology with special qualifications in child neurology providers in Florida →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxcarbazepine | 12 | $463 |
Paid to pharmacies, not to this prescriber.
Other neurology with special qualifications in child neurology in Miami
- Trevor ResnickMiami$230K
- Migvis MonduyMiami$188K
- Elza VasconcellosMiami$170K
- Ian MillerMiami$104K
- Matt LallasMiami$88K
- Marytery FajardoMiami$44K
- Paula SchleiferMiami$31K
- Roberto Lopez-AlberolaMiami$31K
- Anuj JayakarMiami$24K
- Walter BradleyMiami$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.